Gimv et al. lead €36m series-A for G-Therapeutics

LSP and Inkef led the round, while Gimv invested a €6m equity ticket in the business. The investors' syndicate raised €26m of equity for the round, while the Dutch government provided an additional €10m loan.

As part of the deal, Gimv partner Patrick Van Beneden, Wellington general partner Regina Hodits, Inkef senior director Jan Keltjens and LSP partner John de Konig will join the management team.

The fresh capital will enable the company to undertake clinical trials for the sale of its neuro-stimulation device in the European and US markets. The investors' syndicate is available to invest additional capital in the company, unquote" understands.

Company
Founded in 2014 and headquartered in Lausanne, Switzerland, G-Therapeutics is developing an implantable neuro-stimulator device for incomplete spinal cord injuries. The device supports patients' motor function recovery by stimulating the spinal cord.

The company has a technology development centre in Eindhoven, the Netherlands, and does not generate revenues.

People
Life Sciences Partners – John de Konig (partner).
Inkef Capital – Jan Keltjens (senior director).
Gimv – Patrick Van Beneden (partner).
Wellington Partners – Regina Hodits (general partner).
G-Therapeutics – Grégoire Courtine (co-founder, chief scientific officer); Sjaak Deckers (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• DACH
• Switzerland
• Netherlands
• Gimv
• Life Science Partners
• Wellington Partners